BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, November 14, 2011
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
11/11
cls
|
|
Inhibitex
Inc. (NASDAQ:INHX)
|
Deutsche
Bank
|
Robyn
Karnauskas
|
Price
target
|
Buy
|
9%
|
$9.29
|
|
Karnauskas
raised her target to $15 from $9 after Inhibitex reported topline data
showing that once-daily 200 mg INX-189 as monotherapy reduced median HCV RNA
from baseline to day seven by 4.25 log10 IU/mL in the first cohort of a Phase
Ib trial in treatment-naive patients with chronic HCV genotype 1 infection (see
BioCentury, Nov. 7). She anticipates a 2017 launch of the phosphoramidate
nucleoside analog NS5B polymerase inhibitor, with peak annual worldwide sales
of $5B.
|
|
pSivida
Corp. (NASDAQ:PSDV; ASX:PVA)
|
Ladenburg
Thalmann
|
Juan
Sanchez
|
Downgrade
|
Neutral
(from buy)
|
-51%
|
$2.03
|
|
Sanchez
also removed his target after FDA issued a second complete response for an
NDA from partner Alimera Sciences Inc. (NASDAQ:ALIM) for Iluvien to
treat diabetic macular edema (DME) associated with diabetic retinopathy. According
to Alimera, FDA said the "significant" risks of adverse events in
the Phase III FAME trials were not outweighed by the benefits and asked the
company to conduct two additional trials to show that Iluvien is safe and
effective (see B11). The injectable insert delivers fluocinolone
acetonide (FA); Alimera has rights from pSivida
|
198
words displayed of
658
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]